Grail Q3 Earnings: Massive Stock Gains, Mediocre Performance - I'm Still Not Sold [Seeking Alpha]
GRAIL, Inc. (GRAL)
Company Research
Source: Seeking Alpha
Galleri test's PATHFINDER 2 study showed promising early cancer detection, yet questions remain about detection rates, pricing, and broad adoption, in my view. GRAL's stock has surged 185% since my last Hold call, despite lack of FDA approval and ongoing uncertainty around reimbursement, market size, and future profitability. I maintain a Hold rating, as too many uncertainties persist regarding FDA approval, insurer adoption, and the path to sustainable profitability. Goodboy Picture Company/E+ via Getty Images Investment Overview GRAIL, Inc. ( GRAL ), the Menlo Park, California-based cancer testing company, reported its Q3 earnings and business updates yesterday. The company earned $36.2m of revenues - up 26% year-on-year - in the quarter, with revenues from its flagship More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving v
Show less
Read more
Impact Snapshot
Event Time:
GRAL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRAL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRAL alerts
High impacting GRAIL, Inc. news events
Weekly update
A roundup of the hottest topics
GRAL
News
- GRAIL (NASDAQ:GRAL) was given a new $110.00 price target on by analysts at Morgan Stanley.MarketBeat
- GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- GRAIL to Present at Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- GRAIL (NASDAQ:GRAL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $85.00 to $105.00. They now have a "buy" rating on the stock.MarketBeat
- GRAIL Reports Third Quarter 2025 Financial ResultsPR Newswire